SCHEMBL18630923

SCHEMBL18630923

COc1ccc(CNC(=O)[C@](C)(F)CO)cc1

nearest known ligand 0.56

Predicted protein targets (top 17)

geneUniProtsupporting neighboursconfidence
NPC1 O15118 3/20 0.55
RAB9A P51151 2/20 0.55
MEN1 O00255 1/20 0.55
EPHX2 P34913 1/20 0.55
KMT2A Q03164 1/20 0.55
NR1H4 Q96RI1 1/20 0.55
L3MBTL1 Q9Y468 1/20 0.55
HPGD P15428 2/20 0.52
HDAC3 O15379 2/20 0.52
HDAC1 Q13547 2/20 0.52
HDAC4 P56524 1/20 0.52
HDAC6 Q9UBN7 1/20 0.52
ALDH1A1 P00352 5/20 0.51
PKM P14618 1/20 0.51
GAA P10253 1/20 0.50
LMNA P02545 1/20 0.48
SMN1; SMN2 Q16637 1/20 0.48

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL18630924 1.00 NPC1 (0.55) NPC1RAB9AMEN1EPHX2KMT2A
SCHEMBL621937 0.85 NPC1 (0.57) NPC1RAB9AMEN1EPHX2KMT2A
SCHEMBL506516 0.84 HDAC3 (0.60) NPC1RAB9AMEN1EPHX2KMT2A
SCHEMBL14254916 0.83 NPC1 (0.61) NPC1RAB9AMEN1EPHX2KMT2A
SCHEMBL18630728 0.82 NPC1 (0.55) NPC1RAB9AMEN1EPHX2KMT2A
SCHEMBL28760659 0.82 NPC1 (0.55) NPC1RAB9AMEN1EPHX2KMT2A
SCHEMBL18630940 0.79 NPC1 (0.46) NPC1RAB9AMEN1EPHX2KMT2A
SCHEMBL18630942 0.79 NPC1 (0.46) NPC1RAB9AMEN1EPHX2KMT2A
SCHEMBL181181 0.78 ALDH1A1 (0.57) NPC1RAB9AMEN1EPHX2KMT2A
SCHEMBL28760642 0.78 KMT2A (0.50) NPC1RAB9AMEN1EPHX2KMT2A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 15 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-3350170-B1 HETEROARYL COMPOUNDS AS IRAK INHIBITORS AND USES THEREOF MERCK PATENT GMBH (DE) 2022-01-26 EP disclosed
CN-108290879-B Heteroaryl compounds as IRAK inhibitors and uses thereof 默克专利有限公司 2022-01-11 CN disclosed
CN-108602776-B Heteroaryl compounds as IRAK inhibitors and uses thereof 默克专利有限公司 2021-12-03 CN disclosed
EP-3350177-B1 HETEROARYL COMPOUNDS AS IRAK INHIBITORS AND USES THEREOF MERCK PATENT GMBH (DE) 2021-07-07 EP disclosed
US-10392375-B2 Heteroaryl compounds as IRAK inhibitors and uses thereof MERCK PATENT GMBH (DE) 2019-08-27 US disclosed
US-10059701-B2 Heteroaryl compounds as IRAK inhibitors and uses thereof MERCK PATENT GMBH (DE) 2018-08-28 US disclosed
US-20180237426-A1 HETEROARYL COMPOUNDS AS IRAK INHIBITORS AND USES THEREOF MERCK PATENT GMBH (DE) 2018-08-23 US disclosed
US-20180237413-A1 HETEROARYL COMPOUNDS AS IRAK INHIBITORS AND USES THEREOF MERCK PATENT GMBH (DE) 2018-08-23 US disclosed
EP-3350170-A1 HETEROARYL COMPOUNDS AS IRAK INHIBITORS AND USES THEREOF Merck Patent GmbH (DE) 2018-07-25 EP disclosed
EP-3350177-A1 HETEROARYL COMPOUNDS AS IRAK INHIBITORS AND USES THEREOF Merck Patent GmbH (DE) 2018-07-25 EP disclosed
US-9969710-B2 Heteroaryl compounds as IRAK inhibitors and uses thereof MERCK PATENT GMBH (DE) 2018-05-15 US disclosed
WO-2017049069-A1 HETEROARYL COMPOUNDS AS IRAK INHIBITORS AND USES THEREOF MERCK PATENT GMBH (DE) 2017-03-23 WO disclosed
US-20170081307-A1 HETEROARYL COMPOUNDS AS IRAK INHIBITORS AND USES THEREOF MERCK PATENT GMBH (DE) 2017-03-23 US disclosed
WO-2017049068-A1 HETEROARYL COMPOUNDS AS IRAK INHIBITORS AND USES THEREOF MERCK PATENT GMBH (DE) 2017-03-23 WO disclosed
US-20170081317-A1 HETEROARYL COMPOUNDS AS IRAK INHIBITORS AND USES THEREOF MERCK PATENT GMBH (DE) 2017-03-23 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20180237426-A1 HETEROARYL COMPOUNDS AS IRAK INHIBITORS AND USES THEREOF IRAK2, IRAK3, IRAK1 NPC1 674/4885RAB9A 2746/4885MEN1 3661/4885
US-20170081317-A1 HETEROARYL COMPOUNDS AS IRAK INHIBITORS AND USES THEREOF IRAK2, IRAK3, IRAK1 NPC1 674/4885RAB9A 2746/4885MEN1 3661/4885
US-20180237413-A1 HETEROARYL COMPOUNDS AS IRAK INHIBITORS AND USES THEREOF IRAK2, IRAK3, IRAK1 NPC1 674/4885RAB9A 2746/4885MEN1 3661/4885
US-10392375-B2 Heteroaryl compounds as IRAK inhibitors and uses thereof IRAK2, IRAK3, IRAK1 NPC1 674/4885RAB9A 2746/4885MEN1 3661/4885
US-10059701-B2 Heteroaryl compounds as IRAK inhibitors and uses thereof IRAK2, IRAK3, IRAK1 NPC1 674/4885RAB9A 2746/4885MEN1 3661/4885
US-20170081307-A1 HETEROARYL COMPOUNDS AS IRAK INHIBITORS AND USES THEREOF IRAK2, IRAK3, IRAK1 NPC1 674/4885RAB9A 2746/4885MEN1 3661/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.